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A New Alternative Approach 
for RhD Incompatibility; 
Determination Fetal RhD Status 
via Biosensor Technology
Ebru Dündar Yenilmez, Umut Kökbaş and Abdullah Tuli
Abstract
Prenatal detection of the fetal RHD status in early stage of pregnancy is 
observed to be useful in the management of RhD incompatibility to identify 
fetuses at risk of hemolytic disease. The routine use of antenatal and postnatal 
anti-D prophylaxis reduces the incidence of hemolytic disease of the fetus and 
newborn. Cell-free fetal DNA in maternal plasma is in use today for routine geno-
typing fetal RHD status. Fetal RhD antigens can be detected in the blood of RhD-
negative pregnant women using a nanopolymer-coated biosensor and could be an 
alternative method for medical diagnosis. We detected RhD-positive fetal antibod-
ies with biosensor in maternal blood of RhD-negative mothers. The electrochemi-
cal measurements were performed on a PalmSens potentiostat and corundum 
ceramic-based screen-printed gold electrode. The demonstrated method has a dif-
ferent view for the detection of fetal RhD status in early pregnancy. The biosensor 
technology is useful and can be carried out rapidly in clinical diagnosis. Biosensors 
are also reproducible methods which give results quickly compared to noninvasive 
fetal RHD genotyping with real-time PCR-based techniques. We suggest that this 
method could become an alternative part of fetal RHD genotyping from maternal 
plasma as a prenatal screening in the management of RhD incompatibility.
Keywords: RhD incompatibility, fetal RhD, biosensor, hemolytic disease,  
RhD antigen
1. Introduction
The discovery of circulating fetal DNA by Lo et al. [1] has opened new possibili-
ties for noninvasive prenatal diagnosis for investigators. It has been shown that this 
new source of fetal DNA also could be used for noninvasive prenatal determination 
of fetal RhD genotyping using the plasma of RhD-negative pregnant women [2]. 
RhD genotyping from maternal plasma is a valuable method to identify pregnancies 
that has a risk of hemolytic disease of the fetus and newborn (HDFN) [3].
The HDFN is caused by IgG antibodies of the mother that cross the placenta to 
red cell surface antigens and facilitate destruction to the immune defense of fetal 
red cells or erythroid progenitors. This causes a significant rate of morbidity and 
mortality for the fetus. RhD antigen of the rhesus system is the most commonly 
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implicated antigen [4, 5]. Prophylaxis after delivery with anti-D immunoglobulin 
reduces the alloimmunization of RhD-negative women [4]. RhD alloimmunization 
has to be monitored for fetal anemia in complicated pregnancies for effective pre-/
postnatal transfusion treatment to prevent the baby from hydrops fetalis [3, 6].
Postnatal prophylaxis was used since the 1960s, with serology test used to identify 
the baby’s RhD status [7]. The routine antenatal prophylaxis in the third trimester 
of pregnancy is now a standard implementation in many countries [4, 8, 9]. This 
application reduces the maternal sensitization and the HDFN in babies [7].
Invasive procedures should be avoided in alloimmunized pregnant women 
because of the risk of transplacental hemorrhage (amniocentesis has the risk up to 
17%), and the risk of pregnancy loss was found to be up to 2% after amniocentesis 
and chorionic villous sampling (CVS), respectively [10].
In this chapter we aimed to share our experiences about the determination 
of fetal RhD genotyping with cffDNA and detection of fetal RhD antigens from 
maternal blood using a new biosensor as a candidate method for management of 
RhD incompatibility.
2. RhD incompatibility and management
The knowledge about the fetal RhD type supports the management of alloim-
munized pregnancies in RhD-negative women [11, 12].
Prophylaxis after delivery is offered only to RhD-negative women who have 
given birth to an RhD-positive baby [9, 13]. This prevents babies from rhesus dis-
ease and reduces maternal sensitization. Routine antenatal anti-D prophylaxis use 
was first introduced in the mid-1990s. The sensitization rates were then reported to 
reduce from 1.2% for the earlier policy to 0.28% [7]. Commonly in white popula-
tion, however, about 38% of these women would be carrying an RhD-negative 
fetus and thus receive anti-RhD immunoglobulin, a pooled human plasma product, 
unnecessarily [14, 15]. Fetal RHD genotyping with cell-free fetal DNA (cffDNA) 
is accepted as a useful method by obstetricians in early pregnancy for the manage-
ment of RhD incompatibility. Since 2001, several European countries use cffDNA 
in maternal blood for noninvasive prenatal diagnosis of fetal RhD status [3]. There 
is also change in the measurement method in the hemolysis detection. This invasive 
method which detects the optical density at a wavelength of 450 nm in amnion fluid 
replaced by detect the fetal anemia by the Doppler measurement of the peak veloc-
ity of systolic blood flow in the middle cerebral artery [16].
3. Fetal RhD genotyping with cell-free fetal DNA
Prenatal care strategies for the fetus with RhD have been changed significantly 
during the last few decades. Discovered cffDNA from plasma of pregnant women 
by Lo et al., in 1997, has been used for the noninvasive detection of fetal RhD status 
which avoids RhD-negative women from antenatal anti-RhD prophylaxis [17–20].
3.1 Methods and sample preparation
3.1.1 Sample preparation
Maternal blood (10 cc) was collected from each pregnant woman and placed 
into an EDTA tube. Centrifugation step was applied within 1 h (at 1600 × g, 10 min) 
after separating maternal plasma. After centrifugation the plasma was removed 
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carefully from the collection tubes and transferred into polypropylene tubes. 
Another centrifugation step was done at 16,000 × g (10 min). The plasma superna-
tants removed to new polypropylene tubes and stored at −20°C until other pro-
cesses. Collected plasmas were thawed, and the DNA was automatically extracted 
from 1 mL of plasma as reported previously [9, 21, 22].
3.1.2 Fetal RhD genotyping
RHD genes (exons 5 and 7) were analyzed from isolated cffDNA samples. The 
oligonucleotide primers used to perform real-time quantitative PCR are reported in 
Table 1 [9]. The gene of DYS14 was tested to confirm the presence of male fetal DNA, 
and the beta globin (β-globin) gene was used as a reference to confirm the presence 
of cffDNA [10]. Real-time PCR performed in a LightCycler 480 (Roche Applied 
Science, Basel, Switzerland) using 96-well plates. The PCR mixture was 50 μL in total 
volume that contains 300 nM of each primer, 50 nM probe, 2 × TaqMan Universal 
PCR master mix (Roche Diagnostics, Basel, Switzerland), and 15 μL of template 
DNA of plasma samples. The PCR cycling conditions were as follows. Incubation 
step was 50°C for 2 min and 95°C for 10 min. Amplification step was 95°C 15 s and 
60°C 60 s (50 cycles). The β-globin gene protocol was the initialization step at 95°C 
for 10 min, followed by 95°C 15 s, 57°C 10 s, and 72°C 10 s (40 cycles). Samples were 
analyzed in triplicate. Calibration curves were run also for each analysis [21].
The clinical features of the subjects studied (mean age and week of pregnancy) 
are shown in Table 2. Fifteen fetuses were found to be RhD-negative females. The 
RhD status of the fetus was predicted in 70 pregnancies in our study. The gender 
determination of the fetuses was shown in Table 3.
We have shown that fetal RHD genotyping by multiplex real-time PCR is 
applicable and readily performed, with a high accuracy rate, as a routine clinical 
test in prenatal diagnostic laboratories in Turkey. This method avoids unnecessary 
Primer Sequence (5′–3′) Label
RHD exon 7
Forward GGGTGTTGTAACCGAGTGCTG None
Reverse CCGGCTCCGACGGTATC None
TaqMan probe CCCACAGCTCCATCATGGGCTACAA FAM-TAMRA
RHD exon 5
Forward CGCCCTCTTCTTGTGGATG None
Reverse GAACACGGCATTCTTCCTTTC None
TaqMan probe TCTGGCCAAGTTTCAACTCTGCTCTGCT VIC-TAMRA
DYS14
Forward CATCCAGAGCGTCCC TGG None
Reverse TTCCCCTTTGTTCCCCAAA None
TaqMan probe CGAAGCCGAGCTGCCCATCA FAM-TAMRA
Beta globin
Forward ACACAACTGTGT TCACTAGC None
Reverse CAACTTCATCCACGTTCACC None
TaqMan probe GAAGTCTGCCGTTACTGCCCTG LC-Red
Table 1. 
Primer and probe sequences used in RHD genotyping [9].
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immunoprophylaxis in RhD-negative women bearing RhD-negative fetuses. We 
suggest that RHD genotyping should become an essential part of prenatal screening 
in the management of RhD incompatibility [9].
4. Biosensor in use to detect fetal RhD in maternal blood
Nowadays biosensors are universal devices which is used in biomedical diag-
nosis such as point-of-care monitoring of treatment and disease progression, drug 
discovery, forensics, and biomedical research [23]. They are widely used in different 
areas of healthcare [24]. The two main examples of biosensors are pregnancy tests 
and glucometers which are very successful devices. Biosensors have different trans-
ducing mechanisms based on signal generation (such as an electrochemical or opti-
cal signal) following the formation of antigen-antibody complexes [25]. Antibodies, 
enzymes, and synthetic biomolecules that are high-affinity reagents can be coupled 
to the transducer in order to provide specificity of the biosensors [23, 26].
We designed a new nanopolymer-coated electrochemical biosensor which is spe-
cific for the detection of fetal RhD antigens in the blood of pregnant women and results 
compared with cffDNA RHD genotyping with real-time PCR [26]. Biosensor technol-
ogy is reproducible which can be used many times. The results can be generated quickly 
within a few minutes when compared to noninvasive fetal RHD genotyping with 
real-time PCR-based techniques. We suggest that biosensor technology could become a 
candidate method in early pregnancy in the management of RhD incompatibility.
4.1 Materials and methods
The bioelectrochemical measurements were performed with PalmSens potentio-
stat systems and gold working electrode combined with the auxiliary Au/Pd (98/2%) 
electrode and the reference Ag/AgCl electrode. Thermostatic working cell, magnetic 
stirrer, automatic pipets, and Milli-Q ultrapure water were used in the experiments.
Gestation 
weeks
N RhD positive, n 
(%)
RhD negative, n 
(%)
Accuracy of RHD and sex 
genotyping, %
Male Female Male Female
6–12 38 10 18 3 7 100
13–28 20 3 5 7 5 100
29–40 12 6 2 1 3 100
Subtotal 19 25 11 15
Total 70 44 (62.8%) 26 (37.2%) 100
Table 3. 
Fetal RhD and sex status of maternal plasma samples [9].
RhD status Age (years) Gestational age Immunization
Χ ± SD (min–max) Χ ± SD (min–max) Yes (n, %) No (n, %)
RhD-negative (n = 26) 29.1 ± 6.0 (20–39) 20.2 ± 8.6 (10–38) 12 (46.2) 14 (53.8)
RhD-positive (n = 44) 28.6 ± 6.1 (18–39) 16.9 ± 6.9 (9–38) 11 (25.0) 33 (75.0)
Table 2. 
Clinical features of the study population [9].
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4.1.1 Preparation procedure of the Au electrode surface
Cleaning electrode. First off all, the base of the working electrode surface was 
polished with alumina. And then the polished working electrode was sonicated 
in pure ethanol and Milli-Q ultrapure water for 10 min for removing undesired 
absorbable particles, respectively. For the last step of the electrode cleaning, five 
successive cyclic voltammogram sweeps were taken with bare working electrode 
between −1.0 and +1.0 V in 0.1 M HNO3 solution.
RhD antibody immobilization onto Au electrode surface. Poly(Hema-Mac) 
nanopolymer was immobilized on the clean electrode’s surface at room tem-
perature via anilin (20 μL anilin and 20 μL RhD antibody). For trapping the 
antibody, a cross-linking agent (2.5% glutaraldehyde) was used. The modified 
working electrode was cleaned with Milli-Q ultrapure water for removing 
unbinding materials.
Principle of the electrobiochemical measurement. The measurement is based on 
the oxidation-reduction reactions of the RhD antibodies. All the measurements per-
formed with thermostatic reaction cell included phosphate buffer (50 mM, pH 7.0) 
and potassium ferrocyanide [K4Fe(CN)6] as mediator complex, at 35°C. The charge 
transfer capacitance (electrochemical potential difference) of antigen-antibody 
interaction difference was measured by biosensor system (Figure 1).
Preparation of the samples. The working group has 26 RhD-negative primigravi-
das. All of them were admitted to the Department of Gynecology and Obstetrics 
and to the Department of Medical Biochemistry for prenatal diagnosis in differ-
ent gestational ages (8th–36th weeks) that were analyzed in biosensor study for 
RhD status (Table 4). Written informed consent that was approved by the Ethics 
Committee of the Faculty of Medicine of Cukurova University was obtained from 
each subject. Blood samples were collected at ethylenediaminetetraacetic acid 
(EDTA) tube (Becton Dickinson, Bangkok, Thailand). Blood group test was identi-
fied by the Blood Bank Centre using slide/tube agglutination test, which includes 
antibodies against red blood cell antigens.
4.2 RhD antibody immobilization
UV polymerization of anilin was used for RhD antibody immobilization. Anilin’s 
reduction potential is reducing at the UV light. A reversible manner was showed 
on the uncovered working electrode of the cyclic voltammogram of redox probe 
Fe(CN)6
4−/3− (Figure 2). To inhibit the charge transfer among redox probe in solu-
tion on the Au electrode, a bioactive layer was applied on the surface of the elec-
trode. The reversible behavior of the cyclic voltammograms turned into a capacitive 
shape (Figure 2).
Figure 1. 
The principle of the biosensor [26].
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4.3 Biosensors optimization trials
Working condition optimization studies were performed to determine the most 
suitable working conditions for using the biosensor. For this aim, the mediator con-
centration, cross-linker concentration, RhD antibody concentration, temperature 
effect, pH, and repeatability were studied.
Concentration of RhD antibody. Determination of the antibody concentration 
effect on the biosensor response, different RhD antibody concentrations (0.05, 
0.10, 0.15, 0.20 ng/mL) were applied on the surface of biosensor. The RhD antibod-
ies optimum concentration was determined at 0.10 ng/mL.
Mediator and cross-linker concentration. In order to investigate the effect of 
the mediator concentration on the biosensor response, potassium ferrocyanide 
of 1.25 and 2.5 mg/dL was used in the preparation of the biosensor. To determine 
the effect of cross-linker concentration on the biosensor, the concentrations of 
glutaraldehyde of 12.5 and 2.5% were used. The optimum was value obtained 
at 2.5%. According to the results obtained from the experiments, the media-
tor complex of 1.25 mg/dL was assigned as the most effective result for the 
biosensor.
Figure 2. 
RhD biosensors cyclic voltammogram for the immobilization steps. Red line: uncovered gold electrode; blue line: 
UV polymerized. (Working conditions: incubation time 1 h for RhD antibody; 50 mM electrochemical redox 
probe solution; and mediator complex pH 7.0 potassium ferrocyanide [K4Fe(CN)6]). For detection of RhD 
antigen in maternal sample, the optimal curve of the biosensors potential range was 0.2–1.4 V [26].
Table 4. 
Clinical features of the samples in biosensor study for RhD status [26].
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The pH effect. For the pH values’ effect on the biosensor response, different 
buffer systems were investigated. For this aim, acetate (50 mM, pH 5.0 ± 5.5), phos-
phate (50 mM, pH 6.0 ± 6.5 ± 7.0 ± 7.5), and Tris-HCl (50 mM, 8.0 ± 8.5) buffers 
were used. The optimum pH value was found at 7.0 due to 100% activity rate. Above 
and below pH 7.0 can cause a decrease in the biosensor response.
Temperature effect. To examine the temperature effect on the biosensor 
response, the assay was performed by different temperatures (10 ± 55°C). The 
optimum working temperature of the biosensor system was detected as 35°C. The 
biosensor response is directly increased with temperature until 35°C, but further 
increase in temperature caused a decrease on the biosensor response.
Repeatability. Determination of the repeatability of the biosensor experiments 
were also studied for 1 μM RhD concentration (n = 10). From the assays the mean 
value (x)̄, standard deviation (SD), and coefficient of variation (CV %) were found 
to be 2.68 ± 0.06 μM and 2.23%, respectively. From the results, the repeatability of 
the biosensor response can be accepted as well as within the given concentration of 
RhD according to the 95% confidence interval.
4.4 Characterization of RhD antibody biosensor
The graphic shown as Figure 3 is the concentrations of RhD in different gestational 
age of pregnant women. The slope of the curves increased with the increasing fetal RhD 
antigen concentration which depends on gestational ages of the samples (Figure 3).
Linearity. The linearity study for the RhD biosensor was obtained in concentra-
tion range between 1 and 250 ng/mL. At higher concentrations, standard curve 
showed a deviation from linearity.
Fetal RHD genotyping. The cffDNA used for fetal RhD status of the fetus is 
studied in 26 pregnancies with multiplex real-time PCR for RHD gene exons 5 and 7. 
Twenty-one of 26 cffDNA were detected as RhD positive, and 5 of 26 were detected 
as RhD negative (the same results as detection with RhD biosensor). The results of 
the fetuses were confirmed after the delivery by serological and molecular tests.
Figure 3. 
Detection of increasing fetal RhD antigen with biosensor in different gestational age and mother’s blood. Sloped 
line 1: RhD-negative sample; sloped line 2: sample 8th week of gestation; sloped line 3: sample 13th week of 
gestation; sloped line 4: sample 21th week of gestation; sloped line 5: sample 36th week of gestation [26].
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5. Conclusions
The new biosensor design, which detects RhD status of the fetus in the early 
stage of pregnancy in RhD-negative pregnant women blood, is suggested as a 
candidate method in fetal RhD management. RhD antibody is immobilized using 
UV polymerization of anilin. To characterize the electrochemical properties of the 
biosensor surface, impedance measurements were applied. For binding the formed 
stable bioactive layer showed binding of RhD antigen of fetus. The significant 
impedance biosensor response concentration to detect RhD antigen-antibody 
binding was 1 ng/mL RhD. The fetus RhD status was approved with real-time PCR 
fetal RHD genotyping. The detection of the RhD status of the fetus with antigen-
antibody biosensor system has more advantage as being fast compared to the 
noninvasive fetal RHD genotyping using fetal DNA. Up to now, common sero-
logical-based techniques were used for the detection fetal RhD status on delivery. 
There is a requirement for fast, sensitive, and low-cost techniques on clinical and 
molecular diagnostic. Using NIPD for the fetal blood group, detection studies were 
accelerated after the discovery of fetal DNA in maternal plasma. The noninvasive 
technique of fetal RhD status of cffDNA with qPCR has been recently introduced 
and now is a strong alternative for traditional tests in early pregnancy. The early 
detection of RhD status with NIPD is advantageous and also avoids the mother from 
anti-RhD prophylaxis [5, 27]. For the detection of fetal RHD from maternal plasma, 
the fetal DNA extraction is a better way. In the last decade, there were significant 
improvements in the accurate management of pregnancies in RhD-negative preg-
nant women (not immunized and/or alloimmunized) by noninvasive fetal RHD 
genotyping [12, 28].
The fetal nucleated red blood cells (RBCs) are well known in maternal blood 
[29]. Bianchi et al. disclosed that in the first three-month period of the gestation, 
the fetus blood contains plenty of RBCs [30]. The RBC membrane has the RhD 
antigen, and when the fetus genotype is RhD positive, the alloimmunization arise 
when the fetal RBCs enter maternal blood. The cause is the anti-D antibodies 
developed by RhD-negative mother. The fetal RhD antigens can be detected on 
the 30–40th day of pregnancy. During the measurement with biosensor, the fetal 
RhD antigens cause signals (the signals increased in proportion to the gestational 
week). This chemical signals mean that the fetal RhD antigens on fetal RBCs 
bind on the surface of the biosensor that is coated with RhD antibodies (antigen-
antibody complex). In RhD-positive fetuses, this chemical signal is converted into 
an electrical signal by a transducer. In our RhD-negative samples (five of the fetus 
were RhD negative), there was no signal change detected on the biosensor. The 
biosensor detects the fetal RhD-positive antigens in the blood of RhD-negative 
mothers. This study demonstrates an original, quick, reliable, and easy detection 
method with biosensor technologies. The design of an immunospecific biosensor 
offers a candidate noninvasive prenatal detection for fetal RhD status to manage 
the RhD incompatibility between the fetus and mother. This method is able to 
capture fetal RhD antigens in maternal blood in the early stage of pregnancy (8th 
week of pregnancy). The biosensor-based detection of fetal RhD status takes 
several minutes using a gold electrode covered by RhD antibody. The determined 
biosensor method is more suitable, simple to construct, sensitive, and specific and 
does not require any expensive apparatus compared with the routine fetal RhD 
determination in early pregnancy. The biosensor instrument exhibits low cost with 
regard to real-time PCR devices. The biosensors can be used several times (up to 
400-fold) and so decreases the cost. The most commonly used technique for NIPD 
is the qRT-PCR. Studies that based on biosensor technologies for NIPD applica-
tion with cffDNA for monogenic diseases reported previously [31]. Some studies 
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demonstrated PCR-free applications by SPR-imaging [32]. We prepared a study 
which detects fetal RHD genotypes from cffDNA using SPR-based biosensor.
In conclusion, the biosensor-based technologies which have used less amount 
of sample and low cost and determine the RhD status of the fetus in a very short 
time make the biosensors more advantageous than NIPD of RhD based on real-time 
quantitative PCR technologies.
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